Johnson Matthey PLC (LON:JMAT - Get Free Report) insider Stephen Oxley sold 19,554 shares of the stock in a transaction dated Friday, October 18th. The shares were sold at an average price of GBX 1,526 ($19.81), for a total transaction of £298,394.04 ($387,424.10).
Stephen Oxley also recently made the following trade(s):
- On Wednesday, August 21st, Stephen Oxley purchased 21 shares of Johnson Matthey stock. The shares were purchased at an average cost of GBX 1,603 ($20.81) per share, for a total transaction of £336.63 ($437.07).
Johnson Matthey Price Performance
LON JMAT traded up GBX 11 ($0.14) during trading hours on Tuesday, hitting GBX 1,534 ($19.92). The company had a trading volume of 415,535 shares, compared to its average volume of 968,876. The company has a debt-to-equity ratio of 63.15, a quick ratio of 0.76 and a current ratio of 1.45. The firm has a market capitalization of £2.67 billion, a price-to-earnings ratio of 2,618.97, a PEG ratio of 49,242.50 and a beta of 0.95. Johnson Matthey PLC has a 52 week low of GBX 1,428.50 ($18.55) and a 52 week high of GBX 1,917.07 ($24.89). The firm has a 50 day simple moving average of GBX 1,562.02 and a 200 day simple moving average of GBX 1,663.01.
Analyst Upgrades and Downgrades
Separately, Deutsche Bank Aktiengesellschaft restated a "buy" rating and issued a GBX 2,400 ($31.16) price objective on shares of Johnson Matthey in a research note on Monday, June 24th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of GBX 1,993.33 ($25.88).
Get Our Latest Analysis on Johnson Matthey
About Johnson Matthey
(
Get Free Report)
Johnson Matthey is a global leader in science that enables a cleaner and healthier world. With over 200 years of sustained commitment to innovation and technological breakthroughs, they improve the function, performance and safety of their customers’ products. Their science has a global impact in areas such as low emission transport, pharmaceuticals, chemical processing and making the most efficient use of the planet’s natural resources.
Recommended Stories
Before you consider Johnson Matthey, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Johnson Matthey wasn't on the list.
While Johnson Matthey currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2025 and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.